Tests whether guided treatment helps chest pain without blocked coronary arteries
Tests a diagnostic procedure to guide treatment in adults with angina and no blocked arteries.
Key facts
- Who runs it
- NHS Greater Glasgow and Clyde
- Where
- Nijmegen, NetherlandsSee the siteAlso in 3 other countries, 38 sites
- Trial code
- Registry title
- iCorMicA - Stratified Medicine in Angina
- Status
- Recruiting
- People taking part
- 1,500 people, planned
- Started
- 30 Dec 2020
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Disclosure of IDP results
- IDP performed but results not disclosed
- Record updated
- 9 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with symptoms of angina who are already planned for an invasive coronary angiogram and have no blocked main heart artery.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Angina symptoms (typical or atypical) on the Rose and/or Seattle Angina questionnaires, with no blockage in a main coronary artery (diameter >2.5 mm).
- Earlier treatment
- No previous coronary artery bypass surgery.
Main reasons for not taking part
- Invasive angiography is planned mainly for a reason not linked to the coronary arteries (for example valve disease, heart failure)
- Previous coronary artery bypass surgery
- Blockage in a main coronary artery: stenosis >50% and/or fractional flow reserve (FFR) ≤0.80
- Logistical reason (these people enter a follow-up registry)
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age ≥18 years
- A clinical plan for invasive coronary angiography
- Symptoms of angina (typical or atypical) according to the Rose- and/or Seattle Angina questionnaires
- Able to comply with study procedures
- Able to provide informed consent
Who cannot take part
- A non-coronary primary indication for invasive angiography (e.g. valve disease, heart failure)
- History of coronary artery bypass surgery
- Presence of obstructive disease evident in a main coronary artery (diameter >2.5 mm), i.e. a coronary stenosis >50% and/or a fractional flow reserve (FFR) ≤0.80*
- Logistical reason*. *These patients will enter a follow-up registry
Where in Netherlands
Also in 3 other countries, 38 sites
- Radboud university medical centreNijmegen, NetherlandsContact: Peter Damman DrTaking people
About the trial
What the trial wants to find out
The iCorMicA study is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry. The investigators seek to determine whether stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during the invasive management of patients with known or suspected angina but no obstructive coronary artery disease improves symptoms, wellbeing, cardiovascular risk and clinical outcomes.
The 2 groups in the trial
- Intervention Group - Stratified MedicineExisting treatment, for comparison
All randomised participants will receive stratified medicine. The subjects will undergo functional coronary angiography involving guidewire-based coronary function tests (interventional diagnostic procedure, IDP) as an adjunct to invasive coronary angiography. The IDP results will be disclosed to the catheter laboratory clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and IDP findings.
Treatment: Disclosure of IDP results
- Standard Care GroupSham treatment, for comparison
All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also receive the IDP at time of the angiogram. The results of the IDP will be concealed from the catheter laboratory clinician who will be blinded. The cardiac physiologist / clinical scientist will remain unblinded for the purpose of data recording and quality assurance. The sham procedure is intended to be the same as in the Intervention Group. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and IDP findings.
Treatment: IDP performed but results not disclosed
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- International Study of Coronary Microvascular Angina (iCorMicA): a Randomised, Controlled, Multicentre Trial and Registry
- Plain-language title
- Tests whether guided treatment helps chest pain without blocked coronary arteriesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 9 April 2026